United Kingdom· GB-APID-38107211000001108
Beovu 19.8mg/0.165ml solution for injection pre-filled syringes
A brolucizumab product containing brolucizumab, registered in United Kingdom by Novartis Pharmaceuticals UK Ltd. The same ATC class is registered in 13 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Brolucizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC S01LA06 (brolucizumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Brolucizumab · ATC S01LA06
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Brolucizumab
- Manufacturer
- Novartis Pharmaceuticals UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- S01LA06
- ATC class
- Brolucizumab
- Defined daily dose
- 0.0357 DE, IVT
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin07613421029739
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Brolucizumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBEOVUNovartis Europharm Limited, Dublin
- FinlandBeovuNovartis Europharm Limited
- IcelandBeovuNovartis Europharm Limited*
- SwedenBeovu 120 mg/ml Injektionsvätska, lösningNovartis Europharm Limited
- BelgiumBeovu 120 mg/mlNovartis Europharm
- IrelandBeovu 120 mg/ml solution for injection in pre-filled syringeNovartis Europharm Limited
- Japanブロルシズマブ（遺伝子組換え）ノバルティス ファーマ
- NetherlandsBeovu 120 mg/ml, oplossing voor injectieNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Beovu
- Liechtenstein · Beovu
- Norway · Beovu
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/55bcdce4-ee4a-4eff-9a8b-2553d507bb95 GET /v1/drugs/55bcdce4-ee4a-4eff-9a8b-2553d507bb95?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "38107211000001108",
"desc": "Beovu 19.8mg/0.165ml solution for injection pre-filled syringes (Novartis Pharmaceuticals UK Ltd)",
"form": "Solution for injection",
"vpid": "38250711000001109",
"source": "dmd",
"vtm_id": "822955007",
"strength": "120 mg",
"substance": "Brolucizumab",
"ingredient": "Brolucizumab",
"supplier_code": "2920101000001102"
}See everything about brolucizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.